These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 21618986)
21. The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats. Million M; Zhao JF; Luckey A; Czimmer J; Maynard GD; Kehne J; Hoffman DC; Taché Y PLoS One; 2013; 8(9):e73749. PubMed ID: 24040053 [TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists. Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists. Dzierba CD; Sielecki TM; Arvanitis AG; Galka A; Johnson TL; Takvorian AG; Rafalski M; Kasireddy-Polam P; Vig S; Dasgupta B; Zhang G; Molski TF; Wong H; Zaczek RC; Lodge NJ; Combs AP; Gilligan PJ; Trainor GL; Bronson JJ; Macor JE Bioorg Med Chem Lett; 2012 Aug; 22(15):4986-9. PubMed ID: 22749422 [TBL] [Abstract][Full Text] [Related]
24. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210 [TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF₁) receptor antagonists. Ahuja VT; Hartz RA; Molski TF; Mattson GK; Lentz KA; Grace JE; Lodge NJ; Bronson JJ; Macor JE Bioorg Med Chem Lett; 2016 May; 26(9):2184-7. PubMed ID: 27020524 [TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists. Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489 [TBL] [Abstract][Full Text] [Related]
30. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. Gully D; Geslin M; Serva L; Fontaine E; Roger P; Lair C; Darre V; Marcy C; Rouby PE; Simiand J; Guitard J; Gout G; Steinberg R; Rodier D; Griebel G; Soubrie P; Pascal M; Pruss R; Scatton B; Maffrand JP; Le Fur G J Pharmacol Exp Ther; 2002 Apr; 301(1):322-32. PubMed ID: 11907190 [TBL] [Abstract][Full Text] [Related]
31. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor. Yamada Y; Mizutani K; Mizusawa Y; Hantani Y; Tanaka M; Tanaka Y; Tomimoto M; Sugawara M; Imai N; Yamada H; Okajima N; Haruta J J Med Chem; 2004 Feb; 47(5):1075-8. PubMed ID: 14971886 [TBL] [Abstract][Full Text] [Related]
32. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750 [TBL] [Abstract][Full Text] [Related]
33. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. McElroy JF; Ward KA; Zeller KL; Jones KW; Gilligan PJ; He L; Lelas S Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122 [TBL] [Abstract][Full Text] [Related]
34. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. Perrin MH; Sutton SW; Cervini LA; Rivier JE; Vale WW J Pharmacol Exp Ther; 1999 Feb; 288(2):729-34. PubMed ID: 9918582 [TBL] [Abstract][Full Text] [Related]
35. Differential dose effects of central CRF and effects of CRF astressin on pig behavior. Salak-Johnson JL; Anderson DL; McGlone JJ Physiol Behav; 2004 Oct; 83(1):143-50. PubMed ID: 15501501 [TBL] [Abstract][Full Text] [Related]
36. The behavioural and electrophysiological effects of CRF in rat frontal cortex. Zieba B; Grzegorzewska M; Brański P; Domin H; Wierońska JM; Hess G; Smiałowska M Neuropeptides; 2008; 42(5-6):513-23. PubMed ID: 18617263 [TBL] [Abstract][Full Text] [Related]
37. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Tellew JE; Lanier M; Moorjani M; Lin E; Luo Z; Slee DH; Zhang X; Hoare SR; Grigoriadis DE; St Denis Y; Di Fabio R; Di Modugno E; Saunders J; Williams JP Bioorg Med Chem Lett; 2010 Dec; 20(24):7259-64. PubMed ID: 21074436 [TBL] [Abstract][Full Text] [Related]
38. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility. Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140 [TBL] [Abstract][Full Text] [Related]